Correlative analysis of miR-34b and p53 with pathological characteristics of NSCLC

Yang,Shuai; Zhu,Hongyan; Cheng,Qingping

doi:10.3892/ol.2019.10239

Correlative analysis of miR-34b and p53 with pathological characteristics of NSCLC

Authors:
- Shuai Yang
- Hongyan Zhu
- Qingping Cheng
View Affiliations

Affiliations: Xiangyang Center Hospital, Hubei University of Arts and Science, Xiangyang, Hubei 441000, P.R. China, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
Published online on: April 10, 2019 https://doi.org/10.3892/ol.2019.10239
Pages: 5558-5564
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of miR-34b and p53 in non-small cell lung cancer (NSCLC) was investigated to explore its relationship with clinical pathology of NSCLC. Reverse transcription-quantitative PCR (RT-qPCR) method was used to quantitatively analyze miR-34b and p53 in cancer tissue and adjacent paraneoplastic (PTLC) tissue in 54 cases of NSCLC. The relationship between gene expression and clinical pathological data was analyzed. The expression of miR-34b in tumor tissues of NSCLC patients was significantly downregulated in comparison with PTLC. The expression level of miR-34b was negatively correlated with lymph node metastasis. It was positively correlated with the degree of differentiation and negatively correlated with the pathological stage (P<0.05). There was no significant association in the expression of miR-34b with age, sex, histological type, and gross classification (all P>0.05). The expression of p53 in the tumor tissue of NSCLC patients was significantly reduced in comparison with PTLC, and its expression was negatively correlated with the pathological stage, lymph node metastasis, and was positively correlated with the degree of differentiation. The expression of p53 in adenocarcinoma was generally higher than that of squamous cell carcinoma and large cell carcinoma. The expression of p53 in central type cancer was significantly higher than that in peripheral type (P<0.05). The expression of miR-34b and p53 was positively correlated in NSCLC tissues (r=0.797, P<0.001). The high expression of miR-34b and p53 is closely related to the clinical stage and pathological grade of NSCLC. miR-34b and p53 may serve as important tumor markers for NSCLC.

View Figures

View References

1	Su Y, Wang Y, Zhou H, Lei L and Xu L: MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS Lett. 588:1983–1988. 2014. View Article : Google Scholar : PubMed/NCBI
2	Bahce I, Yaqub M, Smit EF, Lammertsma AA, van Dongen GA and Hendrikse NH: Personalizing NSCLC therapy by chara-cterizing tumors using TKI-PET and immuno-PET. Lung Cancer. 107:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
3	Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
4	Sanaei S, Hashemi M, Rezaei M, Hashemi SM, Bahari G and Ghavami S: Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk. Biomed Rep. 5:125–129. 2016. View Article : Google Scholar : PubMed/NCBI
5	Li H, Li X, Ge X, Jia L, Zhang Z, Fang R, Yang J, Liu J, Peng S, Zhou M, et al: MiR-34b-3 and miR-449a inhibit malignant progression of nasopharyngeal carcinoma by targeting lactate dehydrogenase A. Oncotarget. 7:54838–54851. 2016.PubMed/NCBI
6	Hashemi M, Danesh H, Bizhani F, Narouie B, Sotoudeh M, Nouralizadeh A, Sharifiaghdas F, Bahari G and Taheri M: Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer. Cancer Biomark. 18:155–159. 2017. View Article : Google Scholar : PubMed/NCBI
7	Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M and de Marinis F: Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacol Res. 117:406–415. 2017. View Article : Google Scholar : PubMed/NCBI
8	Comel A, Sorrentino G, Capaci V and Del Sal G: The cytoplasmic side of p53's oncosuppressive activities. FEBS Lett. 588:2600–2609. 2014. View Article : Google Scholar : PubMed/NCBI
9	Edwards T, Al-Najjar H, Crosbie P, Martin J, Chaturvedi A, Evison M and Booton R: 89P: Investigating the potential utility of the alternative IASLC nodal staging classification in NSCLC. J Thorac Oncol. 11 (Suppl):S94–S95. 2016. View Article : Google Scholar
10	Yang X and Lin D: Changes of 2015 WHO Histological Classification of Lung Cancer and the clinical significance. Zhongguo Fei Ai Za Zhi. 19:332–336. 2016.(In Chinese). PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Ma ZL, Hou PP, Li YL, Wang DT, Yuan TW, Wei JL, Zhao BT, Lou JT, Zhao XT, Jin Y, et al: MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol. 36:2481–2490. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wang R, Chen XF and Shu YQ: Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics. Am J Cancer Res. 5:32–51. 2014.PubMed/NCBI
15	Hu Z, Hou D, Wang X, You Z and Cao X: TSPAN12 is overexpressed in NSCLC via p53 inhibition and promotes NSCLC cell growth in vitro and in vivo. Onco Targets Ther. 11:1095–1103. 2018. View Article : Google Scholar : PubMed/NCBI
16	Lin X, Xu XY, Chen QS and Huang C: Clinical significance of microRNA-34a in esophageal squamous cell carcinoma. Genet Mol Res. 14:17684–17691. 2015. View Article : Google Scholar : PubMed/NCBI
17	Chen LL, Shen Y, Zhang JB, Wang S, Jiang T, Zheng MQ, Zheng ZJ and Chen CX: Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma. Genet Mol Res. 15:152016. View Article : Google Scholar
18	Tian Q, Jia J, Ling S, Liu Y, Yang S and Shao Z: A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol. 40:67–72. 2014. View Article : Google Scholar : PubMed/NCBI
19	Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y, Li Y, Wu Q and Deng Y: Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer. Oncotarget. 7:8441–8454. 2016.PubMed/NCBI
20	Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, et al: A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget. 7:37250–37259. 2016. View Article : Google Scholar : PubMed/NCBI
21	Balça-Silva J, Sousa Neves S, Gonçalves AC, Abrantes AM, Casalta-Lopes J, Botelho MF, Sarmento-Ribeiro AB and Silva HC: Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res. 32:1603–1609. 2012.PubMed/NCBI
22	Kerr KM and López-Ríos F: Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 27:16–24. 2016. View Article : Google Scholar : PubMed/NCBI
23	Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al: PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 108:v3032015.
24	Wang Z, Chen Z, Gao Y, Li N, Li B, Tan F, Tan X, Lu N, Sun Y, Sun J, et al: DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell lung cancer. Cancer Biol Ther. 11:490–496. 2011. View Article : Google Scholar : PubMed/NCBI